Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Perfusion Imaging | 13 | 2023 | 51 | 2.390 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 12 | 2024 | 198 | 1.780 |
Why?
|
| Echocardiography | 7 | 2023 | 502 | 1.730 |
Why?
|
| Heart Valve Diseases | 5 | 2021 | 95 | 1.660 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2024 | 44 | 1.620 |
Why?
|
| Coronary Artery Disease | 6 | 2015 | 316 | 1.370 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 88 | 1.110 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2021 | 43 | 1.000 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 95 | 0.960 |
Why?
|
| Heart | 4 | 2023 | 283 | 0.930 |
Why?
|
| Aortic Valve Stenosis | 4 | 2021 | 189 | 0.750 |
Why?
|
| Image Enhancement | 2 | 2014 | 192 | 0.750 |
Why?
|
| Echocardiography, Doppler | 3 | 2019 | 133 | 0.720 |
Why?
|
| Aorta | 1 | 2021 | 114 | 0.700 |
Why?
|
| Exercise Test | 5 | 2016 | 252 | 0.690 |
Why?
|
| Aortic Valve | 3 | 2021 | 190 | 0.620 |
Why?
|
| 3-Iodobenzylguanidine | 2 | 2014 | 3 | 0.550 |
Why?
|
| Radiopharmaceuticals | 3 | 2024 | 190 | 0.550 |
Why?
|
| Hyperaldosteronism | 1 | 2016 | 6 | 0.510 |
Why?
|
| Mesalamine | 1 | 2015 | 4 | 0.480 |
Why?
|
| Humans | 42 | 2024 | 63511 | 0.470 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2024 | 98 | 0.470 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2024 | 52 | 0.460 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2015 | 20 | 0.460 |
Why?
|
| Sympathetic Nervous System | 2 | 2014 | 35 | 0.460 |
Why?
|
| Chest Pain | 1 | 2015 | 84 | 0.450 |
Why?
|
| Neuropilin-2 | 1 | 2015 | 40 | 0.440 |
Why?
|
| Myocarditis | 1 | 2015 | 67 | 0.440 |
Why?
|
| Consensus | 3 | 2024 | 205 | 0.440 |
Why?
|
| Radiation Protection | 1 | 2014 | 26 | 0.430 |
Why?
|
| Exercise | 2 | 2012 | 942 | 0.430 |
Why?
|
| Artifacts | 1 | 2015 | 125 | 0.430 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 102 | 0.430 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 3 | 2024 | 11 | 0.420 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 182 | 0.420 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 205 | 0.420 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2015 | 119 | 0.410 |
Why?
|
| Purines | 1 | 2012 | 42 | 0.390 |
Why?
|
| Pyrazoles | 1 | 2012 | 78 | 0.380 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 208 | 0.360 |
Why?
|
| Heart Ventricles | 3 | 2023 | 261 | 0.340 |
Why?
|
| Stroke Volume | 3 | 2019 | 329 | 0.330 |
Why?
|
| Athletes | 1 | 2012 | 109 | 0.330 |
Why?
|
| Exercise Therapy | 1 | 2011 | 104 | 0.330 |
Why?
|
| Cardiovascular Infections | 3 | 2024 | 3 | 0.330 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 1094 | 0.310 |
Why?
|
| Endocarditis | 3 | 2024 | 29 | 0.310 |
Why?
|
| Mitral Valve | 2 | 2024 | 121 | 0.310 |
Why?
|
| Neurons | 1 | 2014 | 923 | 0.290 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 919 | 0.270 |
Why?
|
| Ventricular Function, Left | 2 | 2019 | 268 | 0.260 |
Why?
|
| Hospitalization | 1 | 2014 | 1364 | 0.260 |
Why?
|
| Leukocytes | 2 | 2024 | 103 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 2173 | 0.250 |
Why?
|
| Heart Failure | 1 | 2014 | 914 | 0.250 |
Why?
|
| Reproducibility of Results | 6 | 2024 | 1655 | 0.240 |
Why?
|
| Male | 19 | 2021 | 29927 | 0.240 |
Why?
|
| Prognosis | 5 | 2024 | 1749 | 0.240 |
Why?
|
| Vasodilator Agents | 2 | 2016 | 68 | 0.220 |
Why?
|
| Female | 18 | 2021 | 32912 | 0.220 |
Why?
|
| Angina, Stable | 2 | 2014 | 11 | 0.220 |
Why?
|
| Delphi Technique | 1 | 2024 | 101 | 0.210 |
Why?
|
| Hypertension | 2 | 2021 | 587 | 0.210 |
Why?
|
| Pericardium | 1 | 2023 | 35 | 0.200 |
Why?
|
| Risk Assessment | 4 | 2015 | 2082 | 0.200 |
Why?
|
| Middle Aged | 12 | 2021 | 17644 | 0.200 |
Why?
|
| Heart Atria | 1 | 2023 | 137 | 0.190 |
Why?
|
| Ventricular Remodeling | 2 | 2021 | 83 | 0.190 |
Why?
|
| Registries | 2 | 2017 | 893 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 422 | 0.180 |
Why?
|
| Dilatation | 1 | 2021 | 31 | 0.170 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2021 | 124 | 0.170 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 96 | 0.170 |
Why?
|
| Bioprosthesis | 1 | 2021 | 42 | 0.160 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 113 | 0.150 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2019 | 33 | 0.150 |
Why?
|
| Atrial Pressure | 1 | 2019 | 6 | 0.150 |
Why?
|
| Ventricular Pressure | 1 | 2019 | 30 | 0.150 |
Why?
|
| Cardiac Catheterization | 2 | 2019 | 286 | 0.150 |
Why?
|
| Risk Factors | 6 | 2021 | 5359 | 0.150 |
Why?
|
| Heart Valves | 1 | 2018 | 26 | 0.150 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2021 | 110 | 0.150 |
Why?
|
| Retrospective Studies | 6 | 2021 | 6673 | 0.150 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 5474 | 0.140 |
Why?
|
| Hemodynamics | 2 | 2016 | 250 | 0.140 |
Why?
|
| Acetanilides | 2 | 2014 | 3 | 0.140 |
Why?
|
| Protein Multimerization | 2 | 2015 | 176 | 0.130 |
Why?
|
| Adult | 7 | 2021 | 16837 | 0.130 |
Why?
|
| Data Accuracy | 1 | 2017 | 32 | 0.130 |
Why?
|
| Piperazines | 2 | 2014 | 81 | 0.130 |
Why?
|
| Inservice Training | 1 | 2017 | 86 | 0.130 |
Why?
|
| Aldosterone | 1 | 2016 | 18 | 0.130 |
Why?
|
| Coronary Circulation | 1 | 2016 | 52 | 0.130 |
Why?
|
| Mathematics | 1 | 2016 | 34 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 1147 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2462 | 0.120 |
Why?
|
| Viridans Streptococci | 1 | 2015 | 5 | 0.120 |
Why?
|
| Medical Laboratory Personnel | 1 | 2015 | 9 | 0.120 |
Why?
|
| Vascular Fistula | 1 | 2015 | 8 | 0.120 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 253 | 0.120 |
Why?
|
| Shock | 1 | 2015 | 33 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 980 | 0.120 |
Why?
|
| Endocarditis, Bacterial | 1 | 2015 | 36 | 0.120 |
Why?
|
| Streptococcal Infections | 1 | 2015 | 80 | 0.120 |
Why?
|
| Lafora Disease | 1 | 2014 | 1 | 0.120 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 103 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2014 | 6 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2021 | 5699 | 0.110 |
Why?
|
| Glycogen | 1 | 2014 | 42 | 0.110 |
Why?
|
| Calcinosis | 1 | 2015 | 85 | 0.110 |
Why?
|
| Aortic Diseases | 1 | 2015 | 74 | 0.110 |
Why?
|
| Nausea | 1 | 2015 | 111 | 0.110 |
Why?
|
| Dyspnea | 1 | 2015 | 124 | 0.110 |
Why?
|
| Vomiting | 1 | 2015 | 137 | 0.110 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2015 | 63 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2015 | 197 | 0.110 |
Why?
|
| Triage | 1 | 2015 | 129 | 0.110 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 125 | 0.110 |
Why?
|
| Aged | 9 | 2019 | 14472 | 0.110 |
Why?
|
| ROC Curve | 3 | 2023 | 282 | 0.110 |
Why?
|
| Standard of Care | 1 | 2014 | 27 | 0.110 |
Why?
|
| Proteolysis | 1 | 2015 | 145 | 0.110 |
Why?
|
| Health Status Indicators | 1 | 2014 | 93 | 0.100 |
Why?
|
| Drug Costs | 1 | 2014 | 56 | 0.100 |
Why?
|
| Protein Binding | 2 | 2015 | 1603 | 0.100 |
Why?
|
| Multimodal Imaging | 2 | 2024 | 68 | 0.100 |
Why?
|
| Electric Countershock | 1 | 2014 | 102 | 0.100 |
Why?
|
| Radiation Dosage | 1 | 2014 | 132 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2015 | 218 | 0.100 |
Why?
|
| Adenosine A2 Receptor Agonists | 1 | 2012 | 7 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 196 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 174 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2017 | 444 | 0.100 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 731 | 0.100 |
Why?
|
| Binding Sites | 1 | 2015 | 906 | 0.100 |
Why?
|
| Coronary Disease | 1 | 2013 | 246 | 0.090 |
Why?
|
| Physical Endurance | 1 | 2012 | 48 | 0.090 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 79 | 0.090 |
Why?
|
| Coronary Angiography | 1 | 2012 | 206 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 1592 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2013 | 125 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1991 | 0.090 |
Why?
|
| Myocardium | 1 | 2013 | 279 | 0.090 |
Why?
|
| Sex Factors | 2 | 2012 | 978 | 0.090 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 267 | 0.090 |
Why?
|
| Morbidity | 1 | 2011 | 113 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2014 | 873 | 0.090 |
Why?
|
| Length of Stay | 1 | 2014 | 815 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2010 | 240 | 0.080 |
Why?
|
| United States | 4 | 2024 | 7852 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 540 | 0.070 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2012 | 361 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 724 | 0.070 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 769 | 0.070 |
Why?
|
| Quality of Life | 1 | 2014 | 1230 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 837 | 0.060 |
Why?
|
| Disease Progression | 1 | 2011 | 1173 | 0.060 |
Why?
|
| Age Factors | 1 | 2010 | 1561 | 0.060 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2015 | 111 | 0.060 |
Why?
|
| Prevalence | 2 | 2021 | 1383 | 0.060 |
Why?
|
| Ranolazine | 2 | 2014 | 2 | 0.050 |
Why?
|
| Prosthesis-Related Infections | 1 | 2024 | 34 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 1647 | 0.050 |
Why?
|
| Time Factors | 3 | 2015 | 3770 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2014 | 741 | 0.050 |
Why?
|
| Phantoms, Imaging | 1 | 2023 | 214 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2014 | 373 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2013 | 608 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2024 | 379 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2014 | 753 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2021 | 230 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2023 | 658 | 0.040 |
Why?
|
| Diastole | 1 | 2019 | 91 | 0.040 |
Why?
|
| Algorithms | 1 | 2024 | 1003 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2014 | 2574 | 0.030 |
Why?
|
| Connecticut | 1 | 2015 | 90 | 0.030 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2015 | 19 | 0.030 |
Why?
|
| Debridement | 1 | 2015 | 33 | 0.030 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2015 | 27 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2015 | 57 | 0.030 |
Why?
|
| New York | 1 | 2015 | 145 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 214 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2015 | 80 | 0.030 |
Why?
|
| Oligosaccharides | 1 | 2014 | 54 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 179 | 0.030 |
Why?
|
| Phosphates | 1 | 2014 | 93 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 72 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 221 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2014 | 260 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2014 | 199 | 0.030 |
Why?
|
| Machine Learning | 1 | 2015 | 177 | 0.030 |
Why?
|
| Global Health | 1 | 2015 | 183 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 63 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2014 | 433 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2016 | 554 | 0.030 |
Why?
|
| Perfusion | 1 | 2013 | 72 | 0.030 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2015 | 176 | 0.020 |
Why?
|
| Patient Selection | 1 | 2015 | 490 | 0.020 |
Why?
|
| Technetium | 1 | 2012 | 68 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 851 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2012 | 78 | 0.020 |
Why?
|
| Echocardiography, Stress | 1 | 2012 | 14 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 378 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 312 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 129 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 498 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 936 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2013 | 153 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 864 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2013 | 165 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2013 | 203 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2015 | 496 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 1150 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2015 | 727 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 455 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 790 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 574 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 4700 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2681 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 3301 | 0.020 |
Why?
|